Who
Robert A. Beardsley
Director
Company insider
Files Form 4 as: Director, Arbutus Biopharma; Chief Operating Officer, Galera Therapeutics; Director, Collagenex Pharmaceuticals.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 24 May 2006
- Last trade
- 1 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 7 Oct 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code D | $90K17,948 at $5.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $168K52,533 at $3.20 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $334K78,800 at $4.24 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code F | $502K99,057 at $5.07 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —52,533 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —78,800 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —52,533 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —78,800 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $168K52,533 at $3.20 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $334K78,800 at $4.24 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code F | $502K99,057 at $5.07 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,800 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,800 at $0.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —157,600 at $0.00 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 21 Nov 2022filed 22 Nov 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 21 Nov 2022filed 22 Nov 2022 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code M | $11K10,000 at $1.07 | filing |
| 12 Sep 2022filed 13 Sep 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Sep 2022filed 13 Sep 2022 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code M | $11K10,000 at $1.07 | filing |
| 28 Feb 2022filed 2 Mar 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.